European Commission Approves 4-Week Nivolumab Dosing Schedule in Adjuvant Melanoma

October 24, 2019 – The European Commission has approved nivolumab at a flat dosing schedule of either 240 mg over 30 minutes every 2 weeks, or 480 mg infused over 60 minutes every 4 weeks, for the adjuvant treatment of patients with melanoma who have involvement of lymph nodes or metastatic disease who have undergone complete resection. “The approval of Opdivo two- and four-week flat dosing schedule in the adjuvant melanoma setting is an important … (leggi tutto)